The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease

Journal of Alzheimer's Disease

Volumn 46, Issue 4, 2015, Pages 877-888

  Hansen, Henrik H ^a   Fabricius, Katrine ^a   Barkholt, Pernille ^a   Niehoff, Michael L ^b   Morley, John E ^b,d   Jelsing, Jacob ^a   Pyke, Charles ^e   Knudsen, Lotte Bjerre ^e   Farr, Susan A ^b,c   Vrang, Niels ^a  

^a Gubra   (Denmark)

^b SAINT LOUIS UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NOVO NORDISK A S   (Denmark)

Author keywords

Alzheimer's disease; GLP 1 receptor agonist; hippocampus; liraglutide; memory function; neuroprotection; SAMP8 mouse; stereology

Indexed keywords

LIRAGLUTIDE; AMYLOID BETA PROTEIN; ANTIDIABETIC AGENT;

AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL COUNT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; FOOD INTAKE; HIPPOCAMPAL CA1 REGION; LEARNING; MALE; MEMORY; MEMORY CONSOLIDATION; MOUSE; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SENESCENCE ACCELERATED MOUSE; T-MAZE TEST; AGE; AGING; ANIMAL; AVOIDANCE BEHAVIOR; BLOOD; COMPLICATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; EATING; GENETICS; HIPPOCAMPUS; INBRED MOUSE STRAIN; MAZE TEST; MEMORY DISORDERS; METABOLISM; PATHOLOGY;

AGE FACTORS; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; AVOIDANCE LEARNING; BODY WEIGHT; CELL COUNT; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; HIPPOCAMPUS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, INBRED STRAINS;

EID: 84936990507     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-143090     Document Type: Article

References (62)

1. Qiu C, Kivipelto M, von Strauss E (2009) Epidemiology of Alzheimer's disease: Occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 11, 111-128.
2. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362, 329-344.
3. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1, a006189.
4. Rönnemaa E, Zethelius B, Sundelöf. J, Sundström J, Degerman-Gunnarsson M, Berne C, Lannfelt L, Kilander L (2008) Impaired insulin secretion increases the risk of Alzheimer disease. Neurology 71, 1065-1071.
5. Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R, O'Neill C (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 31, 224-243.
6. Schrijvers EMC, Witteman JCM, Sijbrands EJG, Hofman A, Koudstaal PJ, Breteler MMB (2010) Insulin metabolism and the risk of Alzheimer disease: The Rotterdam Study. Neurology 75, 1982-1987.
7. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 7, 63-80.
8. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE (2012) Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122, 1316-1338.
9. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. JAMA 69, 29-38.
10. Hölscher C, Li L (2010) New roles for insulin-like hormones in neuronal signalling and protection: New hopes for novel treatments of Alzheimer's disease? Neurobiol Aging 31, 1495-1502.
11. Alvarez E, Martínez MD, Roncero I, Chowen JA, García- Cuartero B, Gispert JD, Sanz C, Vázquez P, Maldonado A, de Cáceres J, Desco M, Pozo MA, Blázquez E (2005) The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 92, 798-806.
12. Merchenthaler I, Lane M, Shughrue P (1999) Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403, 261-280.
13. Orskov C, Poulsen SS, Møller M, Holst JJ (1996) Glucagonlike peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 45, 832-835.
14. Secher A, Jelsing J, Baquero AF, Hecksher-Sørensen J, Cowley MA, Dalbøge LS, Hansen G, Grove KL, Pyke C, Raun K, Scha¨ffer L, Tang-Christensen M, Verma S, Witgen BM, Vrang N, Bjerre Knudsen L (2014) The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 124, 4473-4488.
15. Long-Smith CM, Manning S, McClean PL, Coakley MF, O'Halloran DJ, Holscher C, O'Neill C (2013) The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease. Neuromolecular Med 15, 102-114.
16. McClean PL, Hölscher C (2014) Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease. Neuropharmacology 86C, 241-258.
17. McClean PL, Hölscher C (2014) Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacology 76 Pt A, 57-67.
18. Bomba M, Ciavardelli D, Silvestri E, Canzoniero LMT, Lattanzio R, Chiappini P, Piantelli M, Di Ilio C, Consoli A, Sensi SL (2013) Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals. Cell Death Dis 4, e612.
19. Han WN, Hölscher C, Yuan L, Yang W, Wang XH, Wu MN, Qi JS (2013) Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats. Neurobiol Aging 34, 576-588.
20. Reitz C, Mayeux R (2014) Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 88, 640-651.
21. Morley JE, Farr SA, Kumar VB, Armbrecht HJ (2012) The SAMP8 mouse: a model to develop therapeutic interventions for Alzheimer's disease. Curr Pharm Des 18, 1123-1130.
22. Pallas M, Camins A, Smith MA, Perry G, Lee HG, Casadesus G (2008) From aging to Alzheimer's disease: Unveiling "the switch" with the senescence-accelerated mouse model (SAMP8). J Alzheimers Dis 15, 615-624.
23. Armbrecht HJ, Siddiqui AM, Green M, Farr SA, Kumar VB, Banks WA, Patrick P, Shah GN, Morley JE (2014) SAMP8 mice have altered hippocampal gene expression in long term potentiation, phosphatidylinositol signaling, and endocytosis pathways. Neurobiol Aging 35, 159-168.
24. Sisley S, Smith K, Sandoval DA, Seeley RJ (2014) Differences in acute anorectic effects of long-acting GLP-1 receptor agonists in rats. Peptides 58, 1-6.
25. Tatarkiewicz K, Sablan EJ, Polizzi CJ, Villescaz C, Parkes DG (2014) Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor. Am J Physiol Regul Integr Comp Physiol 306, R490-R498.
26. Briyal S, Shah S, Gulati A (2014) Neuroprotective and anti-apoptotic effects of liraglutide in the rat brain following focal cerebral ischemia. Neuroscience 281C, 269-281.
27. DellaValle B, Hempel C, Johansen FF, Kurtzhals JA (2014) GLP-1 improves neuropathology after murine cold lesion brain trauma. Ann Clin Transl Neurol 1, 721-732.
28. Xiong H, Zheng C, Wang J, Song J, Zhao G, Shen H, Deng Y (2013) The neuroprotection of liraglutide on Alzheimer-like learning and memory impairment by modulating the hyperphosphorylation of tau and neurofilament proteins and insulin signaling pathways in mice. J Alzheimers Dis 37, 623-635.
29. Kanoski SE, Rupprecht LE, Fortin SM, De Jonghe BC, Hayes MR (2012) The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology 62, 1916-1927.
30. Flood JF, Farr SA, Uezu K, Morley JE (1998) Age-related changes in septal serotonergic, GABAergic and glutamatergic facilitation of retention in SAMP8 mice. Mech Ageing Dev 105, 173-188.
31. Morley JE, Farr SA, Flood JF (2002) Antibody to amyloid beta protein alleviates impaired acquisition, retention, and memory processing in SAMP8 mice. Neurobiol Learn Mem 78, 125-138.
32. Morley JE, Kumar VB, Bernardo AE, Farr SA, Uezu K, Tumosa N, Flood JF (2000) Beta-amyloid precursor polypeptide in SAMP8 mice affects learning and memory. Peptides 21, 1761-1767.
33. Llorens-Martín M, Blazquez-Llorca L, Benavides-Piccione R, Rabano A, Hernandez F, Avila J, DeFelipe J (2014) Selective alterations of neurons and circuits related to early memory loss in Alzheimer's disease. Front Neuroanat 8, e38.
34. Zola-Morgan S, Squire LR (1993) Neuroanatomy of memory. Annu Rev Neurosci 16, 547-563.
35. Slomianka L, West MJ (2005) Estimators of the precision of stereological estimates: An example based on the CA1 pyramidal cell layer of rats. Neuroscience 136, 757-767.
36. West MJ, Slomianka L, Gundersen HJ (1991) Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231, 482-497.
37. Paxinos G, Franklin K (2004) The Mouse Brain in Stereotaxic Coordinates, Academic Press, London.
38. Sisley S, Gutierrez-Aguilar R, Scott M, D'Alessio DA, Sandoval DA, Seeley RJ (2014) Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J Clin Invest 124, 2456-2463.
39. Flood JF, Morley JE (1992) Early onset of age-related impairment of aversive and appetitive learning in the SAM-P/8 mouse. J Gerontol 47, B52-B59.
40. Bomfim TR1, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. J Clin Invest 122, 1339-1353.
41. McClean PL, Parthsarathy V, Faivre E, Hölscher C (2011) The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 31, 6587-6594.
42. Farr SA, Banks WA, La Scola ME, Flood1 JF, Morley JE (2000) Permanent and temporary inactivation of the hippocampus impairs T-maze footshock avoidance acquisition and retention. Brain Res 872, 242-249.
43. Hammond RS, Tull LE, Stackman RW (2004) On the delay-dependent involvement of the hippocampus in object recognition memory. Neurobiol Learn Mem 82, 26-34.
44. Dudchenko PA (2004) An overview of the tasks used to test working memory in rodents. Neurosci Biobehav Rev 28, 699-709.
45. Ennaceur A (2010) One-trial object recognition in rats and mice: Methodological and theoretical issues. Behav Brain Res 215, 244-254.
46. Gerlai R (1998) A new continuous alternation task in T-maze detects hippocampal dysfunction in mice. A strain comparison and lesion study. Behav Brain Res 95, 91-101.
47. Li G, Cheng H, Zhang X, Shang X, Xie H, Zhang X, Yu J, Han J (2013) Hippocampal neuron loss is correlated with cognitive deficits in SAMP8 mice. Neurol Sci 34, 963-969.
48. Han S, Rudd JA, Hu ZY, Zhang L, Yew DT, Fang M (2010) Analysis of neuronal nitric oxide synthase expression and increasing astrogliosis in the brain of senescence-accelerated-prone 8 mice. Int J Neurosci 120, 602-608.
49. Ma F, Wang H, Chen B, Wang F, Xu H (2011) Metallothionein 3 attenuated the apoptosis of neurons in the CA1 region of the hippocampus in the senescence-accelerated mouse/PRONE8 (SAMP8). Arq Neuropsiquiatr 69, 105-111.
50. Li Y, Tweedie D, Mattson MP, Holloway HW, Greig NH (2010) Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J Neurochem 113, 1621-1631.
51. Parthsarathy V, Hölscher C (2013) Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model. PLoS One 8, e58784.
52. Heppner K, Kirigiti M, Secher A, Paulsen S, Buckingham R, Pyke C, Knudsen L, Vrang N, Grove K (2015) Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology 1, 255-267.
53. del Valle J, Duran-Vilaregut J, Manich G, Pallàs M, Camins A, Vilaplana J, Pelegrí C (2011) Cerebral amyloid angiopathy, blood-brain barrier disruption and amyloid accumulation in SAMP8 mice. Neurodegener Dis 8, 421-429.
54. Zhang X, Li G, Guo L, Nie K, Jia Y, Zhao L, Yu J (2013) Age-related alteration in cerebral blood flow and energy failure is correlated with cognitive impairment in the senescence-accelerated prone mouse strain 8 (SAMP8). Neurol Sci 34, 1917-1924.
55. Hsu TM, Hahn JD, Konanur VR, Lam A, Kanoski SE (2015) Hippocampal GLP-1 receptors influence food intake, meal size, and effort-based responding for food through volume transmission. Neuropsychopharmacology 40, 327-337.
56. Ohta H, Nishikawa H, Hirai K, Kato K, Miyamoto M (1996) Relationship of impaired brain glucose metabolism to learning deficit in the senescence-accelerated mouse. Neurosci Lett 217, 37-40.
57. Gejl M, Rungby J, Brock B, Gjedde A (2014) At the centennial of Michaelis and Menten, competing Michaelis-Menten steps explain effect of GLP-1 on blood-brain transfer and metabolism of glucose. Basic Clin Pharmacol Toxicol 115, 162-171.
58. Flood JF, Harris FJ, Morley JE (1996) Age-related changes in hippocampal drug facilitation of memory processing in SAMP8 mice. Neurobiol Aging 17, 15-24.
59. Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, Greig NH (2003) Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 72, 603-612.
60. Del Valle J, Duran-Vilaregut J, Manich G, Casadesús G, Smith MA, Camins A, Pallàs M, Pelegrí C, Vilaplana J (2010) Early amyloid accumulation in the hippocampus of SAMP8 mice. J Alzheimers Dis 19, 1303-1315.
61. Zhang Y, He JS, Wang X, Wang J, Bao FX, Pang SY, Yin F, Hu HG, Peng XL, Sun WM, Zheng YP, Hou LL, Hong T (2011) Administration of amyloid-β42 oligomer-specific monoclonal antibody improved memory performance in SAMP8 mice. J Alzheimers Dis 23, 551-561.
62. Egefjord L, Gejl M, Møller A, Brændgaard H, Gottrup H, Antropova O, Møller N, Poulsen HE, Gjedde A, Brock B, Rungby J (2012) Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer's disease - protocol for a controlled, randomized double-blinded trial. Dan Med J 59, A4519.